Compare TURB & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | SNGX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 11.2M |
| IPO Year | 2023 | 2006 |
| Metric | TURB | SNGX |
|---|---|---|
| Price | $1.85 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.5M | 833.9K |
| Earning Date | 04-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.37 |
| 52 Week High | $20.44 | $6.23 |
| Indicator | TURB | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 18.80 |
| Support Level | $1.61 | N/A |
| Resistance Level | $2.33 | $1.48 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 23.91 | 0.82 |
Turbo Energy SA is a company that specializes in designing, developing, and distributing equipment for the generation, management, and storage of photovoltaic energy. The company's primary activities include acquiring, distributing, and selling electrical and electronic materials for renewable energy projects, such as solar panels, inverters, chargers, regulators, batteries, and structures. The storage products are managed through a software system optimized by artificial intelligence, which is controlled from the cloud and through the installation inverter. Turbo Energy sells inverters, batteries, and photovoltaic modules to installers and other distributors for residential consumers in Spain. Geographically it operates in Spain, Europe, and Rest of the world.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).